Cost-effectiveness of pharmacotherapy for autoimmune hepatitis (Q36376398)

13 August 2017

1 reference

title

Cost-effectiveness of pharmacotherapy for autoimmune hepatitis (English)

1 reference

13 August 2017

0 references

Michael A Heneghan

1

1 reference

13 August 2017

Thawab Al-Chalabi

series ordinal

2

1 reference

13 August 2017

Ian G McFarlane

series ordinal

3

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

7

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

145-156

1 reference

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Present status of autoimmune hepatitis in Japan--correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Definition and classification of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Current and novel immunosuppressive therapy for autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Management and outcome of pregnancy in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

A systematic review of cost-effectiveness analyses of pharmacogenomic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Short-term cyclosporine induces a remission of autoimmune hepatitis in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.145

21 January 2018

Identifiers

DOI

10.1517/14656566.7.2.145

1 reference

13 August 2017

1 reference